Manufacturing Biotechnologist

We are looking for motivated people to work as Biotechnologists who want to make a difference, delivering advanced innovative treatments to patients with unmet needs and join us at one of our facilities. The purpose of the role is manufacturing commercial and clinical grade viral vector batches within a GMP cleanroom facility.
Our manufacturing team is a critical part of Oxford Biomedica’s operations. We produce multiple clinical and commercial lentiviral vector-based gene therapy products, across seven cleanroom suites in Oxford.
Largescale manufacture of ATMPs within GMP cleanroom facilities including:
Upstream adherent and/or suspension mammalian cell culture, transfection and harvest of viral vector products.
Preparing, cleaning and maintaining the GMP facility including performing viable and non-viable environmental monitoring.
Completing Batch Manufacturing Records in a timely fashion throughout the manufacturing process.
Taking part in continuous improvement initiatives & development of production processes.
Investigating quality incidents, deviations and improving procedures.
BSc Life Sciences or equivalent experience of working within a biological or chemical GMP manufacturing environment.
Self-motivated with a strong focus on safety, quality, details, and results.
Excellent writing skills and computer literacy.
Flexibility to work shifts.
We are a quality and innovation-led cell and gene therapy CDMO with a mission to enable our clients to deliver life changing therapies to patients around the world.
Our innovative solutions and proven expertise allow our clients in the biotech and biopharma industry, to deliver life-saving therapies to reach even more patients.
The success of cell and gene therapy products transforms outcomes for millions of people suffering from some of the world’s worst diseases and medical conditions.
Wellbeing programmes
Development opportunities
State of the art laboratory and manufacturing facilities
Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).
Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
#